

# Ourania Dafni

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9272665/publications.pdf>

Version: 2024-02-01

124  
papers

9,596  
citations

36203

51  
h-index

38300

95  
g-index

125  
all docs

125  
docs citations

125  
times ranked

12579  
citing authors

#	ARTICLE	IF	CITATIONS
1	Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. <i>Cancer Discovery</i> , 2022, 12, 108-133.	7.7	165
2	Essential medicines list in national cancer control plans: a secondary analysis from a global study. <i>Lancet Oncology</i> , The, 2022, 23, e144-154.	5.1	9
3	Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14). <i>Journal of Thoracic Oncology</i> , 2021, 16, 278-288.	0.5	82
4	In-depth immune and molecular profiling of melanoma patients receiving adoptive T-cell therapy reveals biomarkers of efficacy in ATATIL study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2533-2533.	0.8	0
5	Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project. <i>Journal of Thoracic Oncology</i> , 2021, 16, 990-1002.	0.5	37
6	SARS-CoV-2 seroprevalence in healthcare workers of a Swiss tertiary care centre at the end of the first wave: a cross-sectional study. <i>BMJ Open</i> , 2021, 11, e049232.	0.8	10
7	Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 416-425.	0.5	17
8	Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays <sup>™</sup> and cross-validation with resections, in patients with, stage Iâ€”III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort. <i>Modern Pathology</i> , 2020, 33, 792-801.	2.9	28
9	A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1647-1656.	0.5	34
10	EHA evaluation of the ESMOâ€™Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. <i>ESMO Open</i> , 2020, 5, e000611.	2.0	10
11	Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. <i>Lung Cancer</i> , 2019, 134, 127-140.	0.9	156
12	Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). <i>Journal of Thoracic Oncology</i> , 2019, 14, 1086-1094.	0.5	99
13	Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancerâ€™The ETOP NICOLAS trial. <i>Lung Cancer</i> , 2019, 133, 83-87.	0.9	113
14	A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. <i>Lung Cancer</i> , 2019, 131, 95-103.	0.9	40
15	Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. <i>Journal of Clinical Oncology</i> , 2019, 37, 336-349.	0.8	101
16	Breast Cancer Statistics in the European Union: Incidence and Survival across European Countries. <i>Breast Care</i> , 2019, 14, 344-353.	0.8	125
17	A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma. <i>Journal of Translational Medicine</i> , 2019, 17, 391.	1.8	42
18	Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). <i>Annals of Oncology</i> , 2019, 30, 161-165.	0.6	60

#	ARTICLE	IF	CITATIONS
19	Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	326
20	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. <i>Journal of Thoracic Oncology</i> , 2018, 13, 413-425.	0.5	66
21	Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. <i>Clinical Cancer Research</i> , 2018, 24, 3079-3086.	3.2	15
22	Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey. <i>ESMO Open</i> , 2018, 3, e000422.	2.0	50
23	Exploratory Analysis of Single-Gene Predictive Biomarkers in HERA DASL Cohort Reveals That C8A mRNA Expression Is Prognostic of Outcome and Predictive of Benefit of Trastuzumab. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	1.5	5
24	Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry " Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1851-1863.	0.5	6
25	Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients. <i>Annals of Oncology</i> , 2018, 29, x40.	0.6	29
26	Report on the status of women occupying leadership roles in oncology. <i>ESMO Open</i> , 2018, 3, e000423.	2.0	35
27	Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8510-8510.	0.8	20
28	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 435-444.	5.2	172
29	Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, 752-762.	0.5	17
30	ESMO-Magnitude of Clinical Benefit Scale version 1.1. <i>Annals of Oncology</i> , 2017, 28, 2340-2366.	0.6	451
31	Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project. <i>Lung Cancer</i> , 2017, 111, 143-149.	0.9	57
32	Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules. <i>ESMO Open</i> , 2017, 2, e000216.	2.0	20
33	A single-arm phase II trial of afatinib in pretreated patients with advanced NSCLC harboring a HER2 mutation: The ETOP NICHE trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9070-9070.	0.8	21
34	Prevalence and clinical correlation of programmed cell death 1 ligand (PD-L1) expression in patients with resected non-small cell lung cancer (NSCLC): Results from the European Thoracic Oncology Platform (ETOP) Lungscape cohort.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8516-8516.	0.8	0
35	Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015. <i>ESMO Open</i> , 2016, 1, e000055.	2.0	28
36	Selection of the primary end point in an observational cohort study. <i>Journal of Epidemiology and Community Health</i> , 2016, 70, 950-953.	2.0	2

#	ARTICLE	IF	CITATIONS
37	Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab. <i>JAMA Oncology</i> , 2016, 2, 1040.	3.4	73
38	Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. <i>Annals of Oncology</i> , 2016, 27, 1818-1828.	0.6	88
39	VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside. <i>Oncotarget</i> , 2016, 7, 21247-21258.	0.8	86
40	EORTC-ETOP randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with early stage non-small cell lung cancer (NSCLC) after resection and standard adjuvant chemotherapy: PEARLS (NCT02504372).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS8571-TPS8571.	0.8	7
41	Abstract 269: The role of BRCA1 and AEG1 mRNA expression in advanced non-small-cell lung cancer (NSCLC) patients (p) with EGFR activating and pretreatment T790M mutations receiving the combination of erlotinib plus bevacizumab (E+B) in the BELIEF trial. , 2016, , .		0
42	Reply to D. Adkins et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 1225-1226.	0.8	1
43	A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). <i>Annals of Oncology</i> , 2015, 26, 1547-1573.	0.6	635
44	Abstract P5-18-01: TransHERA: The cell cycle regulator p27 predicts benefit from trastuzumab treatment in HER2-positive early breast cancer patients treated within the HERA trial. , 2015, , .		0
45	Abstract P3-06-02: Exploratory analysis of single gene predictive biomarkers in TransHERA DASL cohort reveals that C8A mRNA expression is prognostic of outcome and predictive of benefit of trastuzumab. , 2015, , .		0
46	Combining Cetuximab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: Is More Better?. <i>Journal of Clinical Oncology</i> , 2014, 32, 2929-2931.	0.8	6
47	Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project. <i>Journal of Clinical Oncology</i> , 2014, 32, 2780-2787.	0.8	163
48	Informed Choice of Composite End Points in Cardiovascular Trials. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 170-178.	0.9	21
49	Lungscape: Resected Non-“Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1675-1684.	0.5	31
50	Phase II Design With Sequential Testing of Hypotheses Within Each Stage. <i>Journal of Biopharmaceutical Statistics</i> , 2014, 24, 768-784.	0.4	0
51	Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial. <i>BMC Cancer</i> , 2014, 14, 515.	1.1	26
52	In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients. <i>PLoS ONE</i> , 2014, 9, e99131.	1.1	21
53	Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. <i>BMC Cancer</i> . 2013, 13, 163.	1.1	27
54	Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). <i>Annals of Oncology</i> , 2013, 24, 1011-1017.	0.6	87

#	ARTICLE	IF	CITATIONS
55	Differential Response of Immunohistochemically Defined Breast Cancer Subtypes to Anthracycline-Based Adjuvant Chemotherapy with or without Paclitaxel. <i>PLoS ONE</i> , 2012, 7, e37946.	1.1	54
56	Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 609-619.	1.1	48
57	Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. <i>Lancet Oncology</i> , The, 2011, 12, 236-244.	5.1	575
58	The MARS feasibility trial: conclusions not supported by data. <i>Lancet Oncology</i> , The, 2011, 12, 1093-1094.	5.1	121
59	Landmark Analysis at the 25-Year Landmark Point. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 363-371.	0.9	367
60	Fifteen-year trends in metastatic breast cancer survival in Greece. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 621-631.	1.1	74
61	Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model. <i>BMC Cancer</i> , 2010, 10, 45.	1.1	27
62	Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. <i>Cancer</i> , 2010, 116, 4326-4333.	2.0	35
63	Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 3422-3428.	0.8	228
64	Nuclear Localization of Signal Transducer and Activator of Transcription 3 in Head and Neck Squamous Cell Carcinoma Is Associated with a Better Prognosis. <i>Clinical Cancer Research</i> , 2010, 16, 2427-2434.	3.2	59
65	Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. <i>Journal of Translational Medicine</i> , 2010, 8, 108.	1.8	25
66	Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. <i>Breast Cancer Research</i> , 2010, 12, R24.	2.2	70
67	Reply to S.S. Agarwala et al. <i>Journal of Clinical Oncology</i> , 2009, 27, e84-e84.	0.8	0
68	Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 939-944.	0.8	107
69	Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy. <i>Annals of Oncology</i> , 2009, 20, 49-55.	0.6	39
70	Reply to P. Mohr et al. <i>Journal of Clinical Oncology</i> , 2009, 27, e71-e71.	0.8	0
71	Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 6454-6461.	3.2	97
72	Disease-Free Survival According to Degree of <i>HER2</i> Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 2962-2969.	0.8	164

#	ARTICLE	IF	CITATIONS
73	A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 87-99.	1.1	74
74	Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy. <i>Breast Cancer Research</i> , 2009, 11, R35.	2.2	31
75	Effects of epoetin-alpha on quality of life of cancer patients with solid tumors receiving chemotherapy. <i>Anticancer Research</i> , 2009, 29, 693-702.	0.5	9
76	Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study. <i>British Journal of Cancer</i> , 2008, 99, 1775-1785.	2.9	56
77	Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. <i>Annals of Oncology</i> , 2008, 19, 853-860.	0.6	45
78	Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic Cooperative Oncology Group. <i>Anticancer Research</i> , 2008, 28, 2913-20.	0.5	9
79	Evaluation of the Prognostic and Predictive Value of HER-1/EGFR in Breast Cancer Patients Participating in a Randomized Study with Dose-Dense Sequential Adjuvant Chemotherapy. <i>Oncology</i> , 2007, 72, 388-396.	0.9	16
80	Expression of oncofetal RNA-binding protein CRD-BP/IMP1 predicts clinical outcome in colon cancer. <i>International Journal of Cancer</i> , 2007, 121, 486-494.	2.3	60
81	Pituitary-adrenal responses to human corticotropin-releasing hormone in critically ill patients. <i>Intensive Care Medicine</i> , 2007, 33, 454-459.	3.9	21
82	Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced nonnasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 2006, 17, 1560-1567.	0.6	20
83	Prospective Assessment of Fatigue and Health Status in Greek Patients With Breast Cancer Undergoing Adjuvant Radiotherapy. <i>Oncology Nursing Forum</i> , 2006, 33, 603-610.	0.5	25
84	Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. <i>Annals of Oncology</i> , 2006, 17, 1504-1511.	0.6	41
85	Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon. <i>New England Journal of Medicine</i> , 2006, 354, 709-718.	13.9	593
86	Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 2005, 16, 1762-1771.	0.6	95
87	Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 2004, 15, 1517-1526.	0.6	63
88	Dysthymic Reactions of Women Undergoing Chorionic Villus Sampling for Prenatal Diagnosis of Hemoglobinopathies or Karyotyping. <i>Fetal Diagnosis and Therapy</i> , 2004, 19, 149-154.	0.6	5
89	A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. <i>Annals of Oncology</i> , 2004, 15, 1250-1255.	0.6	27
90	Concomitant Radiochemotherapy vs Radiotherapy Alone in Patients with Head and Neck Cancer: A Hellenic Cooperative Oncology Group Phase III Study. <i>Medical Oncology</i> , 2004, 21, 095-108.	1.2	95

#	ARTICLE	IF	CITATIONS
91	Blood Leptin and Adiponectin as Possible Mediators of the Relation Between Fat Mass and BMD in Perimenopausal Women. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 546-551.	3.1	170
92	The low-dose corticotropin stimulation test in acute traumatic and non-traumatic brain injury: incidence of hypo-responsiveness and relationship to outcome. <i>Intensive Care Medicine</i> , 2004, 30, 1216-1219.	3.9	44
93	Usefulness of Tumor Volumetry as a Prognostic Factor of Survival in Head and Neck Cancer. <i>Strahlentherapie Und Onkologie</i> , 2003, 179, 292-297.	1.0	47
94	8q24 Copy number gains and expression of the c-myc mRNA stabilizing protein CRD-BP in primary breast carcinomas. <i>International Journal of Cancer</i> , 2003, 104, 54-59.	2.3	58
95	Ultrastructural Immunostaining of Infiltrating Ductal Breast Carcinomas with the Monoclonal Antibody H: A Comparative Study with Cytokeratin 8. <i>Ultrastructural Pathology</i> , 2003, 27, 393-407.	0.4	12
96	Association of Proinflammatory Molecules with Apoptotic Markers and Survival in Critically Ill Multiple Organ Dysfunction Patients. <i>Biological Research for Nursing</i> , 2003, 5, 129-141.	1.0	7
97	Ultrastructural Immunostaining of Infiltrating Ductal Breast Carcinomas with the Monoclonal Antibody H: A Comparative Study with Cytokeratin 8. <i>Ultrastructural Pathology</i> , 2003, 27, 393-407.	0.4	0
98	Clinical, immunological, and immunogenetic aspects of autoantibody production against Ro/SSA, La/SSB and their linear epitopes in primary Sjogren's syndrome (pSS): a European multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 398-404.	0.5	60
99	A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin. <i>Cancer</i> , 2002, 94, 452-458.	2.0	64
100	Dose-Dense Sequential Chemotherapy With Epirubicin and Paclitaxel Versus the Combination, as First-Line Chemotherapy, in Advanced Breast Cancer: A Randomized Study Conducted by the Hellenic Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2001, 19, 2232-2239.	0.8	22
101	Lipid-associated sialoprotein in the cerebrospinal fluid. <i>Cancer</i> , 2001, 92, 856-862.	2.0	5
102	Melatonin response to clonidine administration in depression: indication of presynaptic $\alpha_2$ -adrenoceptor dysfunction. <i>Journal of Affective Disorders</i> , 2001, 65, 307-313.	2.0	18
103	Dental and periodontal status of Sjogren's syndrome. <i>Journal of Clinical Periodontology</i> , 2000, 27, 231-235.	2.3	68
104	Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2000, 29, 296-304.	1.6	433
105	Fluorouracil and Leucovorin with or without Interferon Alfa-2a as Adjuvant Treatment, in Patients with High-Risk Colon Cancer. <i>Oncology</i> , 2000, 58, 227-236.	0.9	16
106	Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele. <i>Annals of the Rheumatic Diseases</i> , 2000, 59, 359-367.	0.5	61
107	Pulmonary Capillary Endothelium-Bound Angiotensin-Converting Enzyme Activity in Acute Lung Injury. <i>Circulation</i> , 2000, 102, 2011-2018.	1.6	153
108	Determinants of Hospital Mortality After Coronary Artery Bypass Grafting. <i>Chest</i> , 1999, 115, 1598-1603.	0.4	113

#	ARTICLE	IF	CITATIONS
109	Further Evidence That Routinely Reported Sexually Transmitted Diseases Presage the Evolution of the AIDS Epidemic. <i>Epidemiology</i> , 1999, 10, 788.	1.2	0
110	Postoperative radiation and concomitant bolus fluorouracil with or without additional chemotherapy with fluorouracil and high-dose leucovorin in patients with high-risk rectal cancer: A randomized phase III study conducted by the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 1999, 10, 671-676.	0.6	39
111	Failure of Cytarabine in Progressive Multifocal Leukoencephalopathy Associated with Human Immunodeficiency Virus Infection. <i>New England Journal of Medicine</i> , 1998, 338, 1345-1351.	13.9	343
112	Phrenic Nerve Dysfunction After Cardiac Operations. <i>Chest</i> , 1998, 113, 8-14.	0.4	109
113	Clinical features and evolution of antinuclear antibody positive individuals in a rheumatology outpatient clinic. <i>Journal of Rheumatology</i> , 1998, 25, 886-91.	1.0	16
114	Prevalence of Sjogren's syndrome in a closed rural community. <i>Annals of the Rheumatic Diseases</i> , 1997, 56, 521-525.	0.5	139
115	Routinely Reported Sexually Transmitted Diseases Presage the Evolution of the AIDS Epidemic. <i>Epidemiology</i> , 1997, 8, 449.	1.2	6
116	Analysis of myopathy in a placebo-controlled zidovudine trial. , 1997, 20, 382-385.		28
117	Effects of Low Energy Emission Therapy in Chronic Psychophysiological Insomnia. <i>Sleep</i> , 1996, 19, 327-336.	0.6	35
118	Electroencephalographic changes following low energy emission therapy. <i>Annals of Biomedical Engineering</i> , 1996, 24, 424-429.	1.3	17
119	Determinants of duration of ICU stay after coronary artery bypass graft surgery. <i>British Journal of Anaesthesia</i> , 1996, 77, 208-212.	1.5	44
120	Subjective and objective relaxation effects of low energy emission therapy. <i>Stress and Health</i> , 1994, 10, 5-13.	0.7	5
121	Zidovudine treatment of the AIDS dementia complex: Results of a placebo-controlled trial. <i>Annals of Neurology</i> , 1993, 33, 343-349.	2.8	262
122	Performance evaluation in multicenter clinical trials: Development of a model by the AIDS Clinical Trials Group. <i>Contemporary Clinical Trials</i> , 1993, 14, 523-537.	2.0	10
123	Modeling the Progression of HIV Infection. <i>Journal of the American Statistical Association</i> , 1991, 86, 569-577.	1.8	77
124	Modeling the Progression of HIV Infection. , 0, .		18